R Pokroy1, U R Desai, E Du, Y Li, P Edwards. 1. Department of Ophthalmology and Eye Care Services, Henry Ford Hospital, Detroit, MI 48202, USA. pokroyr@yahoo.com
Abstract
PURPOSE: To assess the efficacy and safety of preoperative intravitreal bevacizumab (IVB) before vitrectomy for diabetic tractional retinal detachment (TRD). METHODS: Using ICD-9 codes, we located all patients with diabetic TRD who underwent 3-port 20-gauge vitrectomy primarily performed by one surgeon between January 2004 and January 2009. Eyes receiving IVB were compared with those not. The following outcomes were compared: visual acuity (VA), duration of surgery, and complication rates. RESULTS: A total of 99 eyes of 90 patients were included in the analysis. In all, 34 patients received IVB on an average of 11.5 (range, 3-30) days previtrectomy. Age was 46.5 and 51.6 in the IVB and non-IVB groups, respectively. VA was improved significantly in both groups: from 20/617 to 20/62 in the IVB group, and from 20/443 to 20/86 in the non-IVB group (P=0.11 between groups). Operating time and postoperative complications (glaucoma, RD, and revitrectomy rate) were similar in both groups. On comparing IVB and non-IVB eyes in younger patients (≤ 40), operating time was shorter (P=0.02) and a trend to better VA in the IVB group was seen. CONCLUSIONS: Preoperative IVB may be a useful adjunct to vitrectomy for severe PDR complicated by TRD, particularly in younger diabetics.
PURPOSE: To assess the efficacy and safety of preoperative intravitreal bevacizumab (IVB) before vitrectomy for diabetic tractional retinal detachment (TRD). METHODS: Using ICD-9 codes, we located all patients with diabetic TRD who underwent 3-port 20-gauge vitrectomy primarily performed by one surgeon between January 2004 and January 2009. Eyes receiving IVB were compared with those not. The following outcomes were compared: visual acuity (VA), duration of surgery, and complication rates. RESULTS: A total of 99 eyes of 90 patients were included in the analysis. In all, 34 patients received IVB on an average of 11.5 (range, 3-30) days previtrectomy. Age was 46.5 and 51.6 in the IVB and non-IVB groups, respectively. VA was improved significantly in both groups: from 20/617 to 20/62 in the IVB group, and from 20/443 to 20/86 in the non-IVB group (P=0.11 between groups). Operating time and postoperative complications (glaucoma, RD, and revitrectomy rate) were similar in both groups. On comparing IVB and non-IVB eyes in younger patients (≤ 40), operating time was shorter (P=0.02) and a trend to better VA in the IVB group was seen. CONCLUSIONS: Preoperative IVB may be a useful adjunct to vitrectomy for severe PDR complicated by TRD, particularly in younger diabetics.
Authors: John O Mason; Cheri T Colagross; Troy Haleman; Jeffrey J Fuller; Milton F White; Richard M Feist; Tracy L Emond; Gerald McGwin Journal: Am J Ophthalmol Date: 2005-08 Impact factor: 5.258
Authors: Raffaello di Lauro; Pio De Ruggiero; Raffaella di Lauro; Maria Teresa di Lauro; Mario Rosario Romano Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-02-05 Impact factor: 3.117
Authors: Stanislao Rizzo; Federica Genovesi-Ebert; Emanuele Di Bartolo; Andrea Vento; Sofia Miniaci; George Williams Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-02-20 Impact factor: 3.117
Authors: J F Arevalo; M Maia; H W Flynn; M Saravia; R L Avery; L Wu; M Eid Farah; D J Pieramici; M H Berrocal; J G Sanchez Journal: Br J Ophthalmol Date: 2007-10-26 Impact factor: 4.638
Authors: Jonathan Yeoh; Christopher Williams; Penny Allen; Robert Buttery; Daniel Chiu; Ben Clark; Rohan Essex; Mark McCombe; Salmaan Qureshi; William G Campbell Journal: Clin Exp Ophthalmol Date: 2008-07 Impact factor: 4.207